Form 4: Phathom Pharmaceuticals COO Azmi Nabulsi Reports Stock Sale to Cover Tax Obligations

Azmi Nabulsi, Chief Operating Officer of Phathom Pharmaceuticals, sold shares to cover tax withholding obligations upon the settlement of restricted stock units.

Summary

• On January 21, 2025, Azmi Nabulsi, the Chief Operating Officer of Phathom Pharmaceuticals, sold 7,886 shares of common stock at a weighted average price of $6.5885.
• The sale was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
• Following the transaction, Nabulsi directly owns 233,390 shares of common stock.
• Nabulsi also indirectly owns 3,578.93 shares through a 401(k) and 785,700 shares through a trust.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range of $6.5855 to $6.6650 upon request.
• Nabulsi acquired 1,973 shares under the employee stock purchase plan in January 2025.

Sentiment

Score: 5

Explanation: This is a neutral event. The sale is related to tax obligations and doesn't necessarily indicate a negative outlook on the company.

Industry Context

This is a routine Form 4 filing, which is common for corporate executives who sell shares of their company's stock. It is important to monitor insider transactions as they can provide insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely to be minimal given the relatively small number of shares sold.

Key Dates